Abstract

In this article, the authors report the perception of anti-TNF biosimilars among payer stakeholders in the big-5 European countries, their rating of level of comfort with extrapolation of clinical data, quality of clinical and economic data available for novel compound evaluations and the perception of suitable target population for biosimilars.